RxDoctor Payments Data

Norma Lopez, MD

Internal Medicine · Maywood, ILNPI 1255482881

Payments from drug & device makers

$1,325in general payments, 2019–2025

Across 17 payments — averaging $77.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Corcept Therapeutics$238
  • AstraZeneca$182
  • Sanofi-aventis U.S. LLC$161
  • Regeneron$135
  • Tolmar, Inc.$108
  • plus $252 from 3 others

What the payments were for

  • Food & beverage$1,325100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,325 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$77,866
Medicare patients
433
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$342,505
JardianceEmpagliflozin210$278,701
TrulicityDulaglutide126$146,479
MounjaroTirzepatide107$131,382
RybelsusSemaglutide38$62,514
JanuviaSitagliptin Phosphate39$61,724
Soliqua 100-33Insulin Glargine/Lixisenatide45$54,811
Humulin R U-500 KwikpenInsulin Regular, Human29$52,675
Tresiba Flextouch U-100Insulin Degludec49$39,129
SynthroidLevothyroxine Sodium254$31,169
TradjentaLinagliptin28$27,779
Novolog FlexpenInsulin Aspart64$25,294
Fiasp FlextouchInsulin Aspart (Niacinamide)35$24,561
InvokanaCanagliflozin25$23,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$21,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$250$405,018220 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$161$54,81145 claims
AstraZenecaFarxiga$182$19,74514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →